PTC Therapeutics Inc [PTCT] stock is trading at $52.07, up 18.66%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The PTCT shares have gain 20.45% over the last week, with a monthly amount glided 30.44%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Robert W. Baird started tracking the stock with Outperform rating on September 04, 2024, and set its price target to $44. Raymond James upgraded its rating to a Mkt Perform. Morgan Stanley downgraded its rating to a Underweight but $28 remained the price target by the analyst firm on December 19, 2023. Wells Fargo started tracking with a Overweight rating for this stock on December 08, 2023, and assigned it a price target of $37. In a note dated October 30, 2023, Oppenheimer upgraded an Outperform rating on this stock but restated the target price of $165.
PTC Therapeutics Inc [PTCT] stock has fluctuated between $22.47 and $47.24 over the past year. Currently, Wall Street analysts expect the stock to reach $47.29 within the next 12 months. PTC Therapeutics Inc [NASDAQ: PTCT] shares were valued at $52.07 at the most recent close of the market. An investor can expect a potential drop of -9.18% based on the average PTCT price forecast.
Analyzing the PTCT fundamentals
PTC Therapeutics Inc [NASDAQ:PTCT] reported sales of 900.66M for the trailing twelve months, which represents a growth of 0.11%. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at -0.14%, Pretax Profit Margin comes in at -0.47%, and Net Profit Margin reading is -0.5%. To continue investigating profitability, this company’s Return on Assets is posted at -0.25, Equity is 0.48 and Total Capital is -0.11. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.27.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 49.85 points at the first support level, and at 47.63 for the second support level. However, for the 1st resistance point, the stock is sitting at 53.63, and for the 2nd resistance point, it is at 55.18.
Ratios To Look Out For
For context, PTC Therapeutics Inc’s Current Ratio is 2.10. In addition, the Quick Ratio stands at 2.04 and the Cash Ratio stands at 0.86. Considering the valuation of this stock, the price to sales ratio is 4.34.
Transactions by insiders
Recent insider trading involved Almstead Zheng Yang, Member of immediate family of, that happened on Dec 02 ’24 when 2060.0 shares were purchased. Officer, Almstead Neil Gregory completed a deal on Dec 02 ’24 to buy 69550.0 shares. Meanwhile, Officer Utter Christine Marie bought 17800.0 shares on Dec 02 ’24.
